ArticleEye (London, England)2014
Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008.
Article in Eye (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between statin use and risk of age-related macular degeneration.Scientific reports · 2015Pooled it
- The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9.Ophthalmology · 2015 · on this mapTrial
- Lipid-lowering drug and complement factor H genotyping-personalized treatment strategy for age-related macular degeneration.iScience · 2024Article
- Different Therapeutic Approaches for Dry and Wet AMD.International journal of molecular sciences · 2024Review
- Repurposing medications for treatment of age-related macular degeneration: Insights from novel approaches to data mining.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Inside out: Relations between the microbiome, nutrition, and eye health.Experimental eye research · 2022Review
- Discovery of sterically-hindered phenol compounds with potent cytoprotective activities against ox-LDL-induced retinal pigment epithelial cell death as a potential pharmacotherapy.Free radical biology & medicine · 2022Article
- The Relationship between Statin and Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Journal of ophthalmology · 2022Review
- The Association Between Consumption of 100% Fruit Juice and Risk of Age-Related Macular Degeneration: Data From the National Health and Nutrition Examination Survey Database.Frontiers in nutrition · 2022Article
- Is There a Relationship between Statin Use and Corneal Specular Microscopy and Topography Findings?Beyoglu eye journal · 2021Article
- REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy.Journal of lipid and atherosclerosis · 2020Review
- Incidence and Risk Factors of Reticular Pseudodrusen Using Multimodal Imaging.JAMA ophthalmology · 2020Article
- The Common Antidiabetic Drug Metformin Reduces Odds of Developing Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2019Article
- The Question of a Role for Statins in Age-Related Macular Degeneration.International journal of molecular sciences · 2018Review
- 'Statins in retinal disease'.Eye (London, England) · 2018Review
- Article
- Recent developments in age-related macular degeneration: a review.Clinical interventions in aging · 2017Review
- Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and TherapeuticsReview
- Update on Clinical Trials in Dry Age-related Macular Degeneration.Middle East African journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo determine the association of hydroxymethylglutarylcoenzyme A (HMG Co-A) reductase inhibitor (statin) use with the prevalence of age-related macular degeneration (AMD).
methodsThis cross-sectional study included 5604 participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2008, ≥ 40 years of age, who were ascertained with regard to the diagnosis of AMD, the use of statins, and comorbidities and health-related behaviors such as smoking.
resultsThe mean age of participants denying or confirming a history of AMD was 68 (SEM 0.90) and 55 (SEM 0.36) years, respectively. Individuals 68 years of age or older who were classified as long-term users of statins had statistically significant less self-reported AMD (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.49-0.84; P=0.002), after adjusting for potential confounding variables. No significant association was found between the prevalence of AMD and statin consumption among subjects between 40 and 67 years of age (OR 1.61, 95% CI 0.85-3.03; P=0.137).
conclusionsOur results suggest a possible beneficial effect of statin intake for the prevention of AMD in individuals 68 years of age or older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.